

CONTENTS

CONTRIBUTORS	ix
PREFACE	xiii
INTRODUCTION	
1 The Evolution of Human Gene Therapy: A Journey from Excessive Hype to Excessive Diffidence to Reality	1
<i>Theodore Friedmann</i>	
VECTOR SYSTEMS	
2 Murine Leukemia Virus–Based Retroviral Vectors	7
<i>Kenneth Cornetta</i>	
3 Lentivirus Vectors	19
<i>Gwendolyn K. Binder and Boro Dropulic</i>	
4 Adenoviral Vectors: History and Perspective	39
<i>Douglas J. Jolly, Estuardo Aguilar-Cordova, and Laura K. Aguilar</i>	
5 Adeno-Associated Virus Vectors	61
<i>Barrie J. Carter</i>	
6 SV40 Virus–Derived Vectors	69
<i>David S. Strayer</i>	
7 Herpes Simplex Virus Vectors	85
<i>Anna-Maria Anesti and Robert S. Coffin</i>	
8 Nonviral Gene Delivery Systems	103
<i>Takeshi Suda and Dexi Liu</i>	

APPLICATIONS

9 Therapeutic Gene Transfer to Skeletal Muscle	123
<i>Paul Gregorevic and Jeffrey S. Chamberlain</i>	
10 Gene Therapy for Cardiovascular Disease	129
<i>Christina A. Pacak, Kerry O. Cresawn, and Barry J. Byrne</i>	
11 Intraarticular Vector Delivery for Inflammatory Joint Disease	137
<i>Haim Burstein</i>	
12 The Respiratory System as a Platform for Gene Delivery	145
<i>Barrie J. Carter</i>	
13 The Brain as a Target for Gene Therapy	153
<i>Pedro R. Lowenstein and Maria G. Castro</i>	
14 Immune Responses to Viral Vectors Injected Systemically or into the CNS	167
<i>Pedro R. Lowenstein and Maria G. Castro</i>	
15 Cancer Vaccines	181
<i>Rimas J. Orentas</i>	
16 Genetically Modified T Cells for Human Gene Therapy	193
<i>James L. Riley and Carl H. June</i>	
17 Lentiviral Vector Delivery of RNAi for the Treatment of HIV-1 Infection	207
<i>Kevin V. Morris and John J. Rossi</i>	
18 Vector Targeting	223
<i>Qiana L. Matthews and David T. Curiel</i>	

THE MANUFACTURE OF GENE THERAPY PRODUCTS

19 The Manufacture of Genetic Viral Vector Products	229
<i>Douglas J. Jolly and Estuardo Aguilar-Cordova</i>	
20 The Manufacture of Adeno-Associated Viral Vectors	245
<i>Richard Peluso</i>	

- 21 Lentivirus Vector Manufacturing** 253
Gwendolyn K. Binder and Boro Dropulic

SAFETY AND REGULATORY CONSIDERATIONS

- 22 Assays for the Release of Viral Vector Gene Therapy Products for Human Clinical Trials** 269
Flavia Borellini

- 23 Safety of Retroviral Vectors: Regulatory and Technical Considerations** 277
Kenneth Cornetta and Carolyn A. Wilson

- 24 Assays for the Quality Control of Lentiviral Vectors** 289
James E. Miskin, Susan M. Kingsman, and Kyriacos A. Mitrophanous

- 25 Assays for Nonviral Vectors** 299
Ralph W. Paul

- 26 Assays for the Release of Cellular Gene Therapy Products** 307
Philip J. Cross and Bruce L. Levine

- 27 Toxicology for Gene Therapy Products: Concepts and Challenges** 319
Russette M. Lyons

- 28 Regulatory Aspects of Gene Therapy Medicinal Products in the European Union** 329
Matthias Schweizer, Christian J. Buchholz, and Klaus Cichutek

FINANCE AND REIMBURSEMENT

- 29 Venture Capital and Biotechnology Startups** 341
Douglas D. Lind

- 30 The Role of Investment Banking in the Growth of Biotechnology Companies** 351
Douglas J. Swirsky

- 31 Managing Reimbursement for Gene Therapy Products** 355
Martin Gold

- INDEX** 361

